GE HealthCare Launches CleaRecon DL: AI-Powered Solution to Enhance CBCT Imaging
GE HealthCare has introduced CleaRecon DL, a cutting-edge AI-driven technology designed to improve the quality of cone-beam computed tomography (CBCT) images.
Powered by a deep-learning algorithm, this solution effectively reduces streak artifacts caused by pulsatile blood flow and contrast distribution changes in arteries, commonly seen in CBCT acquisitions.
The technology, recently FDA 510(k) cleared and CE marked, will be available on the Allia™ platform, providing enhanced image quality for a wide range of procedures, including liver, prostate, neuro, and endovascular aortic repair.
Improving CBCT Image Quality
CBCT plays a vital role in interventional procedures by offering cross-sectional imaging, yet its image quality is often compromised by artifacts caused by the pulsatility of blood vessels.
These artifacts can reduce the accuracy and clarity of reconstructed images, which affects clinicians’ confidence during image interpretation. Despite these challenges, CBCT remains essential for providing detailed visualization of anatomical structures, especially in complex interventional scenarios.
Advancements with CleaRecon DL
CleaRecon DL technology is a major leap in CBCT imaging, providing clinicians with the option of performing procedures with higher accuracy and confidence.
Through artifact removal and better image quality, CleaRecon DL streamlines the user experience and workflow efficiency in interventional suites. This technology builds on GE HealthCare’s portfolio of tools designed to improve clinical outcomes and patient care.
Arnaud Marie, General Manager of Interventional Solutions at GE HealthCare, said, “The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence.”
He added, “This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes.”
Also read: Pathway Unveils AI-Powered Drug Reference and Interaction Checker for Clinicians
AI and Deep Learning for Improved Image Processing
Leveraging deep-learning algorithms, CleaRecon DL is trained to enhance image quality by processing data and performing specialized tasks.
Deep learning, an advanced AI technique, has revolutionized image processing and is known for its ability to analyze large datasets and improve task-specific outputs. Clinical validation of CleaRecon DL has demonstrated impressive results, with 98% of cases showing clearer CBCT images compared to conventional methods.
Moreover, 94% of clinicians reported an improvement in their confidence when interpreting images reconstructed with CleaRecon DL.
